In our next study we plan to examine the clinical outcomes of patients and their association with various injury markers for AKI (e.g. interleukin-18, fatty acid binding proteins and kidney injury molecule 1) which are showing promise in the management of patients with this condition. The gene discussed is HAVCR1; the disease is acute kidney injury.